Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
May 2023
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → 
Studysummary In this study using C3H/HeJ mice, a single subcutaneous injection of the fusion protein PTH-CBD increased anagen hair follicle counts and promoted hair regrowth comparably to daily oral ruxolitinib, potentially by enhancing beta-catenin production and stimulating anagen transition.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study compared the effects of a single subcutaneous injection of parathyroid hormone-collagen binding domain (PTH-CBD) with daily oral administration of the Janus kinase (JAK) inhibitor ruxolitinib on hair follicle counts and hair regrowth in C3H/HeJ mice over 8 weeks. The results showed that PTH-CBD treated mice had an increased number of anagen hair follicles (p<0.05) and improved hair regrowth compared to those treated with ruxolitinib, despite similar immune cell infiltrate. The study also found increased beta-catenin production in hair follicles of PTH-CBD-treated mice. The data suggests that a single dose of PTH-CBD can promote similar hair regrowth to that of daily oral ruxolitinib, potentially by increasing beta-catenin production and stimulating anagen transition of hair follicles.
